The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
The cobas Mass Spec solution Ionify reagent portfolio now covers therapeutic drug monitoring for immunosuppressants and antibiotics
Captured microbes are then neutralized on engineered microbicidal surfaces
Surgical site infections and antimicrobial resistance remain major challenges globally
The move is expected to be crucial during health crises
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company
Subscribe To Our Newsletter & Stay Updated
